Lori Hyden
Obstetrics & Gynecology · Claremore, OKNPI 1104009463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 36.3% of the total. 2025 is the largest year on record at $418, 3.4 times the $124 reported in 2019.
Across 97 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$618
- Astellas Pharma US Inc$222
- Sumitomo Pharma America, Inc.$100
- Pfizer$99
- Mayne Pharma Commercial LLC$89
- Hologic Sales And Service, LLC$84
- plus $493 from 16 others
What the payments were for
- Food & beverage$1,704100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $618 |
| Astellas Pharma US Inc | 13 | $222 |
| Sumitomo Pharma America, Inc. | 5 | $100 |
| Pfizer | 5 | $99 |
| Mayne Pharma Commercial LLC | 4 | $89 |
| Hologic Sales And Service, LLC | 2 | $84 |
| Millicent US Inc | 5 | $82 |
| Therapeuticsmd, Inc. | 5 | $77 |
| Bayer | 3 | $62 |
| Merck | 3 | $44 |
| Myovant Sciences Inc. | 2 | $36 |
| Dermira, Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $24 |
| Agile Therapeutics, Inc. | 1 | $20 |
| Organon | 1 | $17 |
| Lupin Inc. | 1 | $17 |
| Exeltis, USA Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Teleflex LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Mylan Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,704 in reported general payments places this provider in the 60th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lupron DepotLeuprolide Acetate | 13 | $21,853 |
| OrilissaElagolix Sodium | 12 | $13,161 |
| Estradiol | 99 | $5,962 |
| SprintecNorgestimate-Ethinyl Estradiol | 18 | $195 |
| Fluconazole | 23 | $171 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $89 |
| Metronidazole | 11 | $84 |
| Acyclovir | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLupron Depot, Orilissa | $618 | $35,01425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Other obstetrics & gynecology in Claremore
- Tori OdanielOklahoma City$917K
- Kathleen MooreOklahoma City$795K
- Joseph NemcokTulsa$632K
- Jay WilliamsonTulsa$130K
- John SiegleAda$50K
- Lori HubbardTulsa$41K
- Dawn WilsonYukon$36K
- Beverly VavrickaOklahoma City$22K
- Micah RelicTulsa$20K
- Monica ReidOklahoma City$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.